EPIX - ESSA Pharma Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.73
-0.16 (-4.11%)
As of 11:19AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.89
Open3.77
Bid3.70 x 1100
Ask3.76 x 800
Day's Range3.70 - 3.86
52 Week Range0.10 - 5.83
Volume7,001
Avg. Volume29,952
Market Cap21.947M
Beta1.55
PE Ratio (TTM)N/A
EPS (TTM)-2.50
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2018
    CNW Group2 months ago

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2018

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2018

  • Essa Pharma Inc. Regains Compliance with NASDAQ Listing Requirements
    CNW Group2 months ago

    Essa Pharma Inc. Regains Compliance with NASDAQ Listing Requirements

    HOUSTON and VANCOUVER , May 10, 2018 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, Nasdaq: EPIX), a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today that it received a notice from the Nasdaq Listing Qualifications Staff on May 10, 2018 notifying the Company that it regained compliance with the Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the "Nasdaq"). Accordingly, ESSA is in compliance with all applicable listing standards and its common stock will continue to be listed on the Nasdaq and the Nasdaq considers this matter closed.

  • ESSA to present at Bloom Burton & Co. Healthcare Investor Conference 2018
    CNW Group3 months ago

    ESSA to present at Bloom Burton & Co. Healthcare Investor Conference 2018

    ESSA to present at Bloom Burton & Co. Healthcare Investor Conference 2018

  • ESSA Pharma Inc. Announces Completion of Share Consolidation
    CNW Group3 months ago

    ESSA Pharma Inc. Announces Completion of Share Consolidation

    ESSA Pharma Inc. Announces Completion of Share Consolidation

  • ESSA Pharma Enhances R&D Capabilities with Two New Key Hires
    CNW Group3 months ago

    ESSA Pharma Enhances R&D Capabilities with Two New Key Hires

    HOUSTON and VANCOUVER , April 24, 2018 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, announced today the appointments of Han-Jie Zhou , Ph.D., Vice President, Chemistry and Chemistry Manufacturing and Control, and Ronan Le Moigne , Ph.D., Senior Director, Preclinical. Dr. Zhou has more than 18 years of experience in oncology drug discovery and development including medicinal and process chemistry, drug metabolism and pharmacokinetics, chemistry manufacturing and control, project management, and global outsourcing.  Prior to joining ESSA, he was Vice President of Chemistry at Cleave Biosciences, Group Leader at Proteolix and Scientist at Cytokinetics.

  • ESSA Pharma Inc. Announces Share Consolidation
    CNW Group3 months ago

    ESSA Pharma Inc. Announces Share Consolidation

    ESSA Pharma Inc. Announces Share Consolidation

  • Does ESSA Pharma Inc (CVE:EPI) Go Up With The Market?
    Simply Wall St.3 months ago

    Does ESSA Pharma Inc (CVE:EPI) Go Up With The Market?

    For ESSA Pharma Inc’s (TSXV:EPI) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. EPI is exposedRead More...

  • ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
    PR Newswire4 months ago

    ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

    HOUSTON and VANCOUVER , March 28, 2018 /PRNewswire/ -   ESSA Pharma Inc. (" ESSA " or the " Company ") (TSX-V: EPI, NASDAQ: EPIX), a pre-clinical stage pharmaceutical company focused ...

  • ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
    CNW Group4 months ago

    ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

    ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

  • ESSA Pharma Approves Stock Option Plan, RSU Plan, and Option Grants
    PR Newswire5 months ago

    ESSA Pharma Approves Stock Option Plan, RSU Plan, and Option Grants

    HOUSTON and VANCOUVER, Feb. 23, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, hereby announces that on February 21, 2018 the board of directors of the Company ("Board") passed a resolution adopting a new stock option plan (the "New Option Plan") and a restricted share unit plan (the "RSU Plan"). On November 27, 2017, ESSA's common shares ("Common Shares") were delisted from the Toronto Stock Exchange and conditionally listed on the TSX Venture Exchange (the "TSXV"). As a condition to the listing of the Common Shares on the TSXV, the Company is required to adopt a stock option plan that complies with Policy 4.4 – Incentive Stock Options of the TSXV Corporate Finance Manual. In order to comply with this condition, the Board has approved the New Option Plan, which is a fixed number stock option plan that incorporates TSXV requirements and will replace the Company's existing option plan.

  • ESSA Pharma Approves Stock Option Plan, RSU Plan, and Option Grants
    CNW Group5 months ago

    ESSA Pharma Approves Stock Option Plan, RSU Plan, and Option Grants

    ESSA Pharma Approves Stock Option Plan, RSU Plan, and Option Grants

  • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2017
    CNW Group5 months ago

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2017

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2017

  • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2017
    PR Newswire5 months ago

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2017

    HOUSTON and VANCOUVER , Feb. 13, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies ...

  • ESSA to Present at Noble Capital Markets' NobleCon14
    CNW Group6 months ago

    ESSA to Present at Noble Capital Markets' NobleCon14

    ESSA to Present at Noble Capital Markets' NobleCon14

  • ESSA to Present at Noble Capital Markets' NobleCon14
    PR Newswire6 months ago

    ESSA to Present at Noble Capital Markets' NobleCon14

    Nasdaq: EPIX) ("ESSA" or the "Company") today announced that David R. Parkinson, President and Chief Executive Officer, will present at NobleCon14 - Noble Capital Markets' Fourteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida - on Monday January 29th at 1:30pm Eastern Standard Time.

  • ESSA Announces Management Team Change
    PR Newswire6 months ago

    ESSA Announces Management Team Change

    Nasdaq: EPIX) ("ESSA" or the "Company") announced today that  Frank Perabo, M.D., Ph.D., will depart ESSA as the Company's Chief Medical Officer to pursue other opportunities, effective January 31, 2018.  Dr. Perabo will continue to serve the Company in an advisory capacity, and as a member of ESSA's medical advisory committee. ESSA announced in September 2017, its intention to cease clinical development of EPI-506 and  utilize the results from the successfully completed Phase 1 proof of concept trial to expand the preclinical development program around more potent next-generation aniten molecules.  Within the next-generation program, the Company expects to file an Investigational New Drug filing and initiate a Phase 1 clinical trial of the selected next-generation molecule in the first quarter of 2019.  ESSA recently announced the completion of an approximately  US$26 million financing to fund preclinical and clinical development within its next-generation Aniten program.

  • ESSA Announces Management Team Change
    CNW Group6 months ago

    ESSA Announces Management Team Change

    ESSA Announces Management Team Change

  • ESSA expects 180-day extension to regain compliance with the Nasdaq Bid Price Rule
    CNW Group6 months ago

    ESSA expects 180-day extension to regain compliance with the Nasdaq Bid Price Rule

    ESSA expects 180-day extension to regain compliance with the Nasdaq Bid Price Rule

  • ESSA expects 180-day extension to regain compliance with the Nasdaq Bid Price Rule
    PR Newswire6 months ago

    ESSA expects 180-day extension to regain compliance with the Nasdaq Bid Price Rule

    Nasdaq: EPIX) ("ESSA" or the "Company") announced today that it expects to receive a letter (the "Nasdaq Notice") from the Nasdaq Stock Market ("Nasdaq"), granting the Company an additional 180-day period, or until approximately July 16, 2018, to regain compliance with Nasdaq's minimum US$1.00 bid price per share rule (the "Bid Price Rule") for continued listing on the Nasdaq Capital Market.

  • ESSA Completes Second Tranche of Equity Offering, Raising Additional US$5 Million
    PR Newswire6 months ago

    ESSA Completes Second Tranche of Equity Offering, Raising Additional US$5 Million

    NASDAQ: EPIX) ("ESSA" or the "Company") announced today that, further to its previously announced offering of equity securities, it has closed the second tranche of its brokered equity offering, raising an additional US$4 million from a fund managed by Omega Fund Management, LLC ("Omega") as well as the partial exercise by the Canadian agent of its over-allotment option for additional proceeds of approximately US$1 million (collectively, the "Offering"). Together with the initial closing on January 9, 2018 of the brokered equity offering and concurrent non-brokered private placement, the Company has raised total gross proceeds of approximately US$26 million. Pursuant to the Offering, 14,500,000 common shares of the Company ("Common Shares") were issued, of which Omega acquired 9,300,000, representing approximately 8% of the issued and outstanding Common Shares, and Omega acquired 10,700,000 pre-funded common share purchase warrants of the Company ("Warrants", and together with the Common Shares, the "Securities") all at a price of US$0.20 per Security (the "Offering Price").  Each Warrant entitles Omega to acquire, for a nominal exercise price, one Common Share until 4:30 p.m. (Toronto time) on the date that is 60 months following its date of issuance.

  • ESSA Completes Second Tranche of Equity Offering, Raising Additional US$5 Million
    CNW Group6 months ago

    ESSA Completes Second Tranche of Equity Offering, Raising Additional US$5 Million

    ESSA Completes Second Tranche of Equity Offering, Raising Additional US$5 Million

  • ESSA Completes US$21 Million Equity Offering
    PR Newswire6 months ago

    ESSA Completes US$21 Million Equity Offering

    NASDAQ: EPIX) ("ESSA" or the "Company") announced today that, further to its previously announced offering of equity securities, it has closed an initial US$20,325,000 brokered equity offering (the "Offering") and a concurrent US$675,000 non-brokered private placement (the "Private Placement") for aggregate gross proceeds of US$21 million. Pursuant to the Offering, ESSA issued 68,545,000 common shares of the Company ("Common Shares") and 33,080,000 pre-funded common share purchase warrants of the Company ("Warrants", and together with the Common Shares, the "Securities") each at a price of US$0.20 per Security (the "Offering Price") for aggregate gross proceeds of US$20,325,000.  Each Warrant entitles the holder thereof to acquire, for a nominal exercise price, one common share in the capital of the Company (each, a "Warrant Share") until 4:30 p.m. (Toronto time) on the date that is 60 months following its date of issuance.

  • ESSA Completes US$21 Million Equity Offering
    CNW Group6 months ago

    ESSA Completes US$21 Million Equity Offering

    ESSA Completes US$21 Million Equity Offering

  • ESSA Announces Filing of Second Amended and Restated Prospectus Supplement and an Update to Previously Announced Equity Offering
    PR Newswire6 months ago

    ESSA Announces Filing of Second Amended and Restated Prospectus Supplement and an Update to Previously Announced Equity Offering

    NASDAQ: EPIX) ("ESSA" or the "Company") announces a further update to its previously announced equity offering. As previously announced, the Company intends to issue up to 125,000,000 common shares of the Company ("Common Shares") at a price of US$0.20 per Common Share (the "Offering Price") for aggregate gross proceeds of up to US$25 million  (the "Offering").

  • ESSA announces filing of second amended and restated prospectus supplement and an update to previously announced equity offering
    CNW Group6 months ago

    ESSA announces filing of second amended and restated prospectus supplement and an update to previously announced equity offering

    ESSA announces filing of second amended and restated prospectus supplement and an update to previously announced equity offering